Bioxel Pharma Inc.
TSX VENTURE : BIP

Bioxel Pharma Inc.

July 14, 2005 08:00 ET

Bioxel Pharma Takes Another Step Towards Commercial Production of its New Proprietary Taxane Intermediates

SAINTE-FOY, QUEBEC--(CCNMatthews - July 14, 2005) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer and supplier of taxane API's and developer of targeted oncology drugs, today announced the successful pilot scale-up of its taxane intermediates manufactured by semi-synthesis.

Bioxel is focusing its product development resources on expanding the company's taxane product line. Bioxel's proprietary process and taxane intermediates are used to manufacture paclitaxel and docetaxel, two of the most successful anticancer drugs in the world.

"The pilot scale-up of our patent protected process is a key milestone that demonstrates Bioxel's capability to manufacture semi-synthetic docetaxel and paclitaxel on a commercial scale" said Pascal Delmas, President and CEO of Bioxel. "Our objective is to offer to strategic partners access to a high value taxane product line, for which freedom to operate, regulatory compliance, and sustainability of supply are guarantied."

Bioxel intends to file Drug Master Files for its semi-synthetic taxanes in 2005.

Management also states that the marketing campaign for its cGMP natural paclitaxel is proceeding as planned. Bioxel is processing orders from its North-American and European clients, in particular generic drug companies, and is delivering a high quality product at a competitive price.

About Bioxel Pharma

Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane API's and taxane-based proprietary products for improved cancer therapy.

The TSX Venture Exchange has not reviewed the contents of this press release and accepts no responsibility for the adequacy or the accuracy thereof.

This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. These include risks and uncertainties that could affect Bioxel's products under development such as regulatory factors, technological developments and competitive factors. Achievement of the objectives set forth in this release is subject to these risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the realization of financial projections.

Contact Information